Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
BMC Infect Dis ; 16: 254, 2016 06 07.
Artigo em Inglês | MEDLINE | ID: mdl-27266273

RESUMO

BACKGROUND: Currently Norway does not recommend universal varicella vaccination for healthy children. This study assessed susceptibility to varicella-zoster virus (VZV) in the Norwegian population for the first time. METHODS: A national convenience sample of residual sera was tested for anti-VZV IgG by ELISA. We estimated age-specific seropositivity to VZV, controlling for sex and geographical distribution. We assessed differences between the proportions using the chi-square test and multivariable logistic regression. Seroprevalence data were compared to the varicella and herpes zoster-associated consultation rates in patients attending primary healthcare. RESULTS: Although 73.2 % (n = 1,540) of all samples were positive for VZV, only 11.2 % of samples collected from 1-year-olds were seropositive. There was a sharp increase in the proportion of seropositive in 3- and 5-year-olds (40.2 % and 65.4 %, respectively). By the school entry age of 6 years, 69.8 % of children were seropositive. The age-specific annual consultation rate for varicella in primary healthcare peaked in 1-year-olds, with 2,627 cases per 100,000 population. The profile of varicella-related consultations in primary healthcare mirrored the VZV seropositivity profile. The herpes zoster-related consultations in primary healthcare peaked in people over 70 years of age (702 cases per 100,000 population). CONCLUSIONS: VZV seroprevalence in Norway was somewhat lower than in some other European countries. The age-specific varicella-related consultation rates in primary healthcare mirrored the age profile of VZV seroprevalence.


Assuntos
Vacina contra Varicela/provisão & distribuição , Herpes Zoster/epidemiologia , Herpesvirus Humano 3/imunologia , Adolescente , Fatores Etários , Distribuição de Qui-Quadrado , Vacina contra Varicela/economia , Criança , Serviços de Saúde da Criança/estatística & dados numéricos , Pré-Escolar , Suscetibilidade a Doenças , Feminino , Herpes Zoster/sangue , Herpes Zoster/prevenção & controle , Humanos , Lactente , Modelos Logísticos , Masculino , Noruega/epidemiologia , Atenção Primária à Saúde/estatística & dados numéricos , Encaminhamento e Consulta/estatística & dados numéricos , Estudos Soroepidemiológicos , Vacinação
2.
Int J Prison Health ; 12(2): 106-14, 2016 06 13.
Artigo em Inglês | MEDLINE | ID: mdl-27219908

RESUMO

Purpose - Facility-based Varicella zoster virus (VZV) transmission is reported in a Canadian youth offender correctional centre (YOCC). Transmission occurred from an immunocompetent youth offender (YO) with localized Herpes zoster to another immunocompetent single dose vaccinated YO, resulting in Varicella zoster (VZ) breakthrough disease. The purpose of this paper is to identify infection prevention and control (IPAC) measures utilized in this setting. Design/methodology/approach - A retrospective chart and immunization record review was conducted for two VZV cases and 27 exposed YO contacts in order to obtain demographic, clinical and immunization data. Descriptive data analysis was performed. Findings - All VZV cases and exposed contacts were male with an average age of 14.2 and 15.6 years for cases and contacts, respectively. Both cases shared the same living unit in the YOCC. There were 28 identified YO contacts, of whom 70 percent were single dose vaccinated with univalent vaccine, followed by 22 percent with a previous history of Varicella disease. All cases and contacts were born in Canada. No foreign-born populations were involved with this event. Infection control measures included additional precaution management, enhanced surveillance and environmental cleaning. As such, no hospitalizations or post-exposure immunizations were required. Originality/value - This report highlights the role that VZ breakthrough disease could play in fueling an outbreak in a high-risk environment without rapid recognition and implementation of preventative measures. It also underscores the importance of IPAC presence and public health immunization programs within correctional centers to avoid infectious disease threats.


Assuntos
Comportamento do Adolescente , Herpes Zoster/prevenção & controle , Delinquência Juvenil/estatística & dados numéricos , Prisioneiros/estatística & dados numéricos , Prisões/normas , Adolescente , Canadá/epidemiologia , Disparidades nos Níveis de Saúde , Herpes Zoster/sangue , Herpes Zoster/epidemiologia , Herpes Zoster/transmissão , Herpesvirus Humano 3/isolamento & purificação , Herpesvirus Humano 3/patogenicidade , Humanos , Masculino , Prisões/organização & administração , Estudos Retrospectivos , Estudos Soroepidemiológicos
3.
Open Med ; 7(2): e68-73, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24348886

RESUMO

BACKGROUND: Both herpes zoster and malignancy are associated with immunosuppression. However, the association between herpes zoster and the subsequent diagnosis of malignancy is unclear. We undertook this study to assess whether a diagnosis of herpes zoster is a risk factor for subsequent malignancy. METHODS: For this matched retrospective cohort study, a physician billing database was used to identify individuals 18 years of age or older with a diagnosis of herpes zoster and no prior diagnosis of cancer or HIV infection. Individuals with a herpes zoster diagnosis were matched one-to-one to individuals without a herpes zoster diagnosis, and both groups were examined for up to 5 years for diagnosis of cancer. RESULTS: A total of 542,575 individuals with a diagnosis of herpes zoster were identified. Compared with matched controls, these patients were more likely (p < 0.001) to have a history of myocardial infarction, asthma, congestive heart failure, chronic obstructive pulmonary disease, diabetes mellitus, and hypertension. The incidence of cancer was significantly greater among individuals with herpes zoster than among those without herpes zoster, for both men and women and across all time intervals studied (up to 5 years). The greatest adjusted hazard ratio was seen 180 days after a herpes zoster diagnosis (1.19, 95% confidence interval 1.12-1.25); the hazard ratio decreased as the time from herpes zoster diagnosis increased. Lymphoma was the type of cancer with the greatest relative increase in incidence following diagnosis of herpes zoster. INTERPRETATION: There is a risk of malignancy following an episode of herpes zoster in both men and women and in all age groups 18 years and over. The risk is greatest during the first 180 days following the diagnosis of herpes zoster.


Assuntos
Herpes Zoster/epidemiologia , Sistema Imunitário/fisiopatologia , Neoplasias/epidemiologia , Adolescente , Adulto , Distribuição por Idade , Idoso , Biomarcadores , Estudos de Casos e Controles , Comorbidade , Feminino , Herpes Zoster/sangue , Herpes Zoster/imunologia , Humanos , Incidência , Revisão da Utilização de Seguros , Masculino , Pessoa de Meia-Idade , Neoplasias/imunologia , Neoplasias/virologia , Ontário , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de Risco , Distribuição por Sexo , Fatores de Tempo , Adulto Jovem
4.
Reprod Toxicol ; 21(4): 350-82, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16564672

RESUMO

Viral infections during pregnancy may cause fetal or neonatal damage. Clinical intervention, which is required for certain viral infections, relies on laboratory tests performed during pregnancy and at the neonatal stage. This review describes traditional and advanced laboratory approaches and testing methods used for assessment of the six most significant viral infections during pregnancy: rubella virus (RV), cytomegalovirus (CMV), varicella-zoster virus (VZV), herpes simplex virus (HSV), parvovirus B19 and human immunodeficiency virus (HIV). Interpretation of the laboratory tests results according to studies published in recent years is discussed.


Assuntos
Técnicas de Laboratório Clínico , Infecções por Citomegalovirus/diagnóstico , Infecções por HIV/diagnóstico , Herpes Simples/diagnóstico , Herpes Zoster/diagnóstico , Infecções por Parvoviridae/diagnóstico , Rubéola (Sarampo Alemão)/diagnóstico , Infecções por Citomegalovirus/sangue , Infecções por Citomegalovirus/complicações , Feminino , Infecções por HIV/sangue , Infecções por HIV/complicações , Herpes Simples/sangue , Herpes Simples/complicações , Herpes Zoster/sangue , Herpes Zoster/complicações , Humanos , Recém-Nascido , Infecções por Parvoviridae/sangue , Infecções por Parvoviridae/complicações , Parvovirus B19 Humano , Gravidez , Complicações Infecciosas na Gravidez/virologia , Rubéola (Sarampo Alemão)/sangue , Rubéola (Sarampo Alemão)/complicações , Rubéola (Sarampo Alemão)/congênito
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA